Literature DB >> 25385416

Rheumatoid arthritis: Developing new oral targeted therapies for RA can be challenging.

Roy M Fleischmann1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25385416     DOI： 10.1038/nrrheum.2014.187

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

1.  Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.

Authors:  Roy Fleischmann; Joel Kremer; John Cush; Hendrik Schulze-Koops; Carol A Connell; John D Bradley; David Gruben; Gene V Wallenstein; Samuel H Zwillich; Keith S Kanik
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

2.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

Review 3.  Back to the future: oral targeted therapy for RA and other autoimmune diseases.

Authors:  John J O'Shea; Arian Laurence; Iain B McInnes
Journal:  Nat Rev Rheumatol       Date:  2013-02-19       Impact factor: 20.543

4.  Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.

Authors:  Gerd R Burmester; Ricardo Blanco; Christina Charles-Schoeman; Jürgen Wollenhaupt; Cristiano Zerbini; Birgitta Benda; David Gruben; Gene Wallenstein; Sriram Krishnaswami; Samuel H Zwillich; Tamas Koncz; Koshika Soma; John Bradley; Charles Mebus
Journal:  Lancet       Date:  2013-01-05       Impact factor: 79.321

5.  Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.

Authors:  Michael E Weinblatt; Arthur Kavanaugh; Mark C Genovese; David A Jones; Theresa K Musser; Elliott B Grossbard; Daniel B Magilavy
Journal:  J Rheumatol       Date:  2013-02-01       Impact factor: 4.666

6.  Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.

Authors:  Michael E Weinblatt; Arthur Kavanaugh; Ruben Burgos-Vargas; Ara H Dikranian; Gabriel Medrano-Ramirez; Jorge L Morales-Torres; Frederick T Murphy; Theresa Kane Musser; Nicholas Straniero; Angela V Vicente-Gonzales; Elliott Grossbard
Journal:  Arthritis Rheum       Date:  2008-11

7.  A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.

Authors:  Mark C Genovese; Désirée M van der Heijde; Edward C Keystone; Alberto J Spindler; Claude Benhamou; Arthur Kavanaugh; Edward Fudman; Kathy Lampl; Chris O'Brien; Emma L Duffield; Jeffrey Poiley; Michael E Weinblatt
Journal:  J Rheumatol       Date:  2014-09-15       Impact factor: 4.666

8.  Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Authors:  Michael E Weinblatt; Mark C Genovese; Meilien Ho; Sally Hollis; Krystyna Rosiak-Jedrychowicz; Arthur Kavanaugh; David S Millson; Gustavo Leon; Millie Wang; Désirée van der Heijde
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

Review 9.  The SYK tyrosine kinase: a crucial player in diverse biological functions.

Authors:  Attila Mócsai; Jürgen Ruland; Victor L J Tybulewicz
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106
  9 in total
  3 in total

1.  Effects of autophagy on acid-sensing ion channel 1a-mediated apoptosis in rat articular chondrocytes.

Authors:  Ya-Ya Xie; Yue Li; Ren-Peng Zhou; Bei-Bei Dai; Yue-Jiao Qian; Xiao-Shan Wu; Jin-Fang Ge; Wei Hu; Fei-Hu Chen
Journal:  Mol Cell Biochem       Date:  2017-12-22       Impact factor: 3.396

Review 2.  Functions of interleukin-34 and its emerging association with rheumatoid arthritis.

Authors:  Ren-Peng Zhou; Xiao-Shan Wu; Ya-Ya Xie; Bei-Bei Dai; Wei Hu; Jin-Fang Ge; Fei-Hu Chen
Journal:  Immunology       Date:  2016-09-23       Impact factor: 7.397

3.  4-(Hydroxymethyl)catechol Extracted From Fungi in Marine Sponges Attenuates Rheumatoid Arthritis by Inhibiting PI3K/Akt/NF-κB Signaling.

Authors:  Jong Y Lee; Geum J Kim; Jin K Choi; Young-Ae Choi; Na-Hee Jeong; Pil-Hoon Park; Hyukjae Choi; Sang-Hyun Kim
Journal:  Front Pharmacol       Date:  2018-07-20       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.